dalteparin has been researched along with Renal Insufficiency in 73 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized trial (ie, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer [CLOT]) that evaluated secondary prophylaxis of recurrent venous thromboembolism (VTE) in patients with cancer, dalteparin reduced the relative risk by 52% compared to oral vitamin K antagonists (VKAs; hazard ratio = 0." | 9.22 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment. ( Burgers, L; Dranitsaris, G; Shane, L; Woodruff, S, 2016) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 9.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| " This study aims to evaluate whether in clinical practice there is an increase in the occurrence of bleeding in patients with renal insufficiency (RI) during treatment or prophylaxis with dalteparin, and to analyse the risk factors potentially influencing the appearance of such bleeding events." | 8.12 | Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin. ( Corregidor Luna, L; Díaz Gómez, E; García Díaz, B; Iglesias-Peinado, I; Suárez Del Olmo, D, 2022) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 7.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "The objective of this study was to investigate the pharmacodynamic parameters of dalteparin in patients with renal insufficiency under intensive care." | 7.73 | Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. ( Kani, C; Maggina, N; Markantonis, SL; Nicolaou, C, 2006) |
| "Dalteparin induced an increase in C(max) and AUC(0 - infinity) values of free TFPI in the two groups with renal insufficiency that was higher than in healthy volunteers." | 6.72 | Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. ( Achenbach, H; Preiss, C; Preiss, R; Siegemund, A; Stöbe, J, 2006) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 5.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| "In a randomized trial (ie, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer [CLOT]) that evaluated secondary prophylaxis of recurrent venous thromboembolism (VTE) in patients with cancer, dalteparin reduced the relative risk by 52% compared to oral vitamin K antagonists (VKAs; hazard ratio = 0." | 5.22 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment. ( Burgers, L; Dranitsaris, G; Shane, L; Woodruff, S, 2016) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 5.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| "Prospective, double-blind studies in orthopaedic patients have been conducted using the direct thrombin inhibitor dabigatran etexilate (hereafter referred to as dabigatran), with two doses investigated and approved for adults (220 mg and 150 mg once daily) to prevent venous thromboembolism (VTE)." | 4.88 | Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. ( Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N, 2012) |
| " This study aims to evaluate whether in clinical practice there is an increase in the occurrence of bleeding in patients with renal insufficiency (RI) during treatment or prophylaxis with dalteparin, and to analyse the risk factors potentially influencing the appearance of such bleeding events." | 4.12 | Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin. ( Corregidor Luna, L; Díaz Gómez, E; García Díaz, B; Iglesias-Peinado, I; Suárez Del Olmo, D, 2022) |
| "The objective of this report is to describe the roles, responsibilities and recommendations of a 3-member Event Adjudication Committee (EAC) and a 5-member data monitoring committee (DMC) for a prospective multicenter observational study of critically ill patients with renal insufficiency examining the bioaccumulation and bleeding risk associated with dalteparin thromboprophylaxis." | 3.75 | Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis. ( Cook, D; Crowther, M; Douketis, J; Lee, A; Linkins, L; Marshall, JC; Meade, M; O'Donnell, M; Patel, R; Rabbat, C; Sinuff, T; Thabane, L; Treleaven, D; Zytaruk, N, 2009) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 3.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "The objective of this study was to investigate the pharmacodynamic parameters of dalteparin in patients with renal insufficiency under intensive care." | 3.73 | Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. ( Kani, C; Maggina, N; Markantonis, SL; Nicolaou, C, 2006) |
| "Thromboprophylaxis dosing strategies using enoxaparin in elderly patients with renal disease are limited, while dose adjustments or monitoring of anti-Xa levels are recommended." | 2.90 | Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment. ( Chamoun, N; Dimassi, H; Ghanem, G; Ghanem, H; Hachem, A; Hariri, E; Lteif, C; Mansour, H; Zalloum, R, 2019) |
| "4 IU/mL for once-daily dosed tinzaparin and 0." | 2.82 | Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency. ( Knibbe, CAJ; van den Broek, MPH; Verschueren, MV, 2022) |
| " IRIS aimed to assess whether LMWH is at least as safe as UFH in this population." | 2.76 | Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS). ( Clonier, F; Janas, M; Leizorovicz, A; Maddalena, M; Mottier, D; Siguret, V; Stinson, J; Townshend, G, 2011) |
| " As this accumulation depends on heparin chain length and subsequent reticulo-endothelial/renal elimination, LMWHs might have different pharmacodynamic profiles." | 2.73 | Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. ( Aghassarian, M; Bal Dit-Sollier, C; Bergmann, JF; Drouet, L; Heilmann, JJ; Lacut, K; Mahé, I; Mottier, D, 2007) |
| " Other dosing regimens of enoxaparin for specific patient populations should also be assessed for safety and efficacy." | 2.73 | Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. ( Lachish, T; Rudensky, B; Slotki, I; Zevin, S, 2007) |
| "Dalteparin induced an increase in C(max) and AUC(0 - infinity) values of free TFPI in the two groups with renal insufficiency that was higher than in healthy volunteers." | 2.72 | Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. ( Achenbach, H; Preiss, C; Preiss, R; Siegemund, A; Stöbe, J, 2006) |
| "Enoxaparin dosage for obese patients and patients with renal impairment remains controversial." | 2.71 | Dosage of enoxaparin among obese and renal impairment patients. ( Almanric, K; Bazinet, A; Blais, N; Brunet, C; Caron, S; Lalonde, L; Martineau, J; Turcotte, I, 2005) |
| " The elimination half-life was thus estimated to be 6." | 2.71 | Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ( Ankri, A; Bouzamondo, A; Hulot, JS; Lechat, P; Mahé, I; Montalescot, G; Urien, S; Vantelon, C, 2004) |
| "The dosage of the subcutaneous low molecular weight heparin enoxaparin in unstable angina patients undergoing coronary angiogram and coronary angioplasty depends clearly on the renal function." | 2.70 | Enoxaparin in unstable angina patients with renal failure. ( Ankri, A; Choussat, R; Collet, JP; Lison, L; Montalescot, G, 2001) |
| " The elimination half-life increased with the degree of renal impairment, and this relationship was more evident after repeated dosing." | 2.70 | Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. ( Boutouyrie, BX; Guimart, CG; Jariwala, NU; Ozoux, ML; Sanderink, GJ; Shukla, UA, 2002) |
| "Thirty-two critically ill patients with renal failure, treated with high-volume, continuous venovenous hemofiltration." | 2.69 | Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. ( de Pont, AC; Oudemans-van Straaten, HM; Roozendaal, KJ; Zandstra, DF, 2000) |
| "Enoxaparin is a low-molecular-weight heparin (LMWH) that differs substantially from unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic properties." | 2.42 | Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. ( Fareed, J; Hoppensteadt, D; Iqbal, O; Jeske, W; Ma, Q; Sheikh, T; Walenga, J, 2003) |
| " Weight-based dosing is suitable for obese patients." | 1.91 | The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients. ( Hackeng, CM; Knibbe, CAJ; Mast, L; Peeters, MYM; Söhne, M; van den Broek, MPH, 2023) |
| "In patients with renal failure, enoxaparin 20 mg SC daily resulted in a 5." | 1.51 | Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment. ( Chamoun, N; Karaoui, LR; Salameh, P; Tawil, S, 2019) |
| " The risk of under dosing seems less predictable; therefore, anti-Xa assay may be useful in severe clinical situations that require higher anticoagulant activity." | 1.48 | Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure? ( Corrà, L; Di Francesco, V; Facchinetti, R; Fantin, F; Fontana, G; Pellizzari, L; Sepe, A; Zamboni, M, 2018) |
| "In the group with renal failure 12 patients had a GFR between 30 and 50 ml/min/1." | 1.42 | No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency. ( Atiq, F; Leebeek, FW; van den Bemt, PM; van Gelder, T; Versmissen, J, 2015) |
| " Correct dosing is critical to prevent bleeding or thrombosis." | 1.40 | Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment. ( Antonijoan, RM; Ayani, I; Ballester, MR; Borrell, M; Fontcuberta, J; Gich, I; Gutierro, I; Martinez-Gonzalez, J; Rico, S, 2014) |
| "Enoxaparin sodium has predictable pharmacokinetics that allow for simplified dosing without laboratory monitoring." | 1.38 | Enoxaparin outcomes in patients with moderate renal impairment. ( Clairmont, MA; DeCarolis, DD; Johnson, GJ; Leuthner, AM; Rector, TS; Thorson, JG, 2012) |
| "A reduced clearance of some drugs in renal failure is a problem, particularly with drugs that are excreted by the kidney substantially unmetabolised and also have significant toxicity and a low therapeutic ratio." | 1.38 | Utility, or not, of estimates of glomerular filtration rate in modifying drug dosage, with particular reference to enoxaparin. ( Adam, WR, 2012) |
| " While patients with renal impairment have a higher risk of bleeding and dosing of heparins is more difficult, there are no specific recommendations for bridging the latter patients." | 1.35 | Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. ( Hammerstingl, C; Omran, H, 2009) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 1.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| "Hemorrhage was documented in a total of 94 patients (17." | 1.33 | Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice. ( Elis, A; Ellis, MH; Hadari, R; Kovlenko, I; Kozmiakova, M; Shapira, S; Tchuvrero, N; Zissin, R, 2006) |
| "An enoxaparin dosage reduction should be considered in acute coronary syndrome patients with creatinine clearance lower than 50 mL/min." | 1.33 | Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. ( Ankri, A; Collet, JP; Hulot, JS; Lechat, P; Montalescot, G; Urien, S, 2005) |
| "Specific details of dosage and monitoring were collected." | 1.33 | Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. ( Bies, RR; Bobek, MB; Dasta, JF; Feng, Y; Kane-Gill, SL; Pruchnicki, MC, 2005) |
| "Five patients suffering from renal failure developed remarkable cutaneous and subcutaneous nodules or plaques following subcutaneous nadroparin-calcium injections." | 1.32 | Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins. ( Eich, D; Hunzelmann, N; Krieg, T; Scharffetter-Kochanek, K; Weihrauch, J, 2004) |
| " Prospective studies need to be conducted to define the drug's role and dosage adjustments in these patients." | 1.31 | Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. ( Barnes, JF; Gerlach, AT; Pickworth, KK; Seth, SK; Tanna, SB, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.11) | 18.2507 |
| 2000's | 41 (56.16) | 29.6817 |
| 2010's | 22 (30.14) | 24.3611 |
| 2020's | 7 (9.59) | 2.80 |
| Authors | Studies |
|---|---|
| van den Broek, MPH | 2 |
| Verschueren, MV | 1 |
| Knibbe, CAJ | 2 |
| Mast, L | 1 |
| Peeters, MYM | 1 |
| Söhne, M | 1 |
| Hackeng, CM | 1 |
| Smit, R | 1 |
| van Marum, RJ | 1 |
| Péquériaux, NC | 1 |
| Hollander, DA | 1 |
| Bleeker, MWP | 1 |
| Latify, Y | 1 |
| Hermens, WA | 1 |
| Derijks, HJ | 1 |
| Atiq, F | 1 |
| van den Bemt, PM | 1 |
| Leebeek, FW | 1 |
| van Gelder, T | 1 |
| Versmissen, J | 1 |
| Crowther, MA | 4 |
| Cook, DJ | 2 |
| Eich, D | 1 |
| Scharffetter-Kochanek, K | 1 |
| Weihrauch, J | 1 |
| Krieg, T | 1 |
| Hunzelmann, N | 1 |
| Schneiter, S | 1 |
| Huynh-Do, U | 1 |
| Heizmann, M | 1 |
| de Pont, AC | 1 |
| Oudemans-van Straaten, HM | 1 |
| Roozendaal, KJ | 1 |
| Zandstra, DF | 1 |
| Arici, M | 1 |
| Altun, B | 1 |
| Dinler, O | 1 |
| Kiykim, AA | 1 |
| Usalan, C | 1 |
| Erdem, Y | 1 |
| Yasavul, U | 1 |
| Turgan, C | 1 |
| Cağlar, S | 1 |
| Kronenberg, F | 1 |
| König, P | 1 |
| Lhotta, K | 1 |
| Steinmetz, A | 1 |
| Dieplinger, H | 1 |
| Galeano-Valle, F | 1 |
| Pérez-Rus, G | 1 |
| Demelo-Rodríguez, P | 1 |
| Ordieres-Ortega, L | 1 |
| Ortega-Morán, L | 1 |
| Muñoz-Martín, AJ | 1 |
| Medina-Molina, S | 1 |
| Alvarez-Sala-Walther, LA | 1 |
| Del-Toro-Cervera, J | 1 |
| Rico, S | 1 |
| Antonijoan, RM | 1 |
| Ballester, MR | 1 |
| Gutierro, I | 1 |
| Ayani, I | 1 |
| Martinez-Gonzalez, J | 1 |
| Borrell, M | 1 |
| Fontcuberta, J | 1 |
| Gich, I | 1 |
| DeBiase, C | 1 |
| Giuliano, CA | 1 |
| Doshi, M | 1 |
| Ganoff, M | 1 |
| Alexander Paxton, R | 1 |
| Pellizzari, L | 1 |
| Facchinetti, R | 1 |
| Corrà, L | 1 |
| Sepe, A | 1 |
| Fantin, F | 1 |
| Fontana, G | 1 |
| Zamboni, M | 1 |
| Di Francesco, V | 1 |
| Karaoui, LR | 1 |
| Tawil, S | 1 |
| Salameh, P | 1 |
| Chamoun, N | 2 |
| Ghanem, H | 1 |
| Hachem, A | 1 |
| Hariri, E | 1 |
| Lteif, C | 1 |
| Mansour, H | 1 |
| Dimassi, H | 1 |
| Zalloum, R | 1 |
| Ghanem, G | 1 |
| Miyares, MA | 1 |
| DeCarolis, DD | 2 |
| Johnson, GJ | 2 |
| Schliep, S | 1 |
| Kiesewetter, F | 1 |
| Simon, M | 1 |
| Grupp, C | 1 |
| Heinzerling, L | 1 |
| Castellucci, LA | 1 |
| Shaw, J | 1 |
| Giulivi, A | 1 |
| Edwards, C | 1 |
| Carrier, M | 1 |
| Patel, R | 2 |
| Hammerstingl, C | 3 |
| Omran, H | 3 |
| Schmitz, A | 1 |
| Fimmers, R | 1 |
| Silvain, J | 1 |
| Beygui, F | 1 |
| Ankri, A | 5 |
| Bellemain-Appaix, A | 1 |
| Pena, A | 1 |
| Barthelemy, O | 1 |
| Cayla, G | 1 |
| Gallois, V | 1 |
| Galier, S | 1 |
| Costagliola, D | 1 |
| Collet, JP | 4 |
| Montalescot, G | 6 |
| Hoffmann, P | 1 |
| Keller, F | 1 |
| Dahl, OE | 1 |
| Kurth, AA | 1 |
| Rosencher, N | 1 |
| Noack, H | 1 |
| Clemens, A | 1 |
| Eriksson, BI | 1 |
| Elsaid, KA | 1 |
| Collins, CM | 1 |
| Adam, WR | 1 |
| Thorson, JG | 1 |
| Clairmont, MA | 1 |
| Leuthner, AM | 1 |
| Rector, TS | 1 |
| Minichiello, T | 1 |
| Fine, E | 1 |
| Golmard, JL | 1 |
| Dalby, M | 1 |
| Choussat, R | 2 |
| Dumaine, R | 1 |
| Lesty, C | 1 |
| Vignolles, N | 1 |
| Thomas, D | 1 |
| Chow, SL | 1 |
| Zammit, K | 1 |
| West, K | 1 |
| Dannenhoffer, M | 1 |
| Lopez-Candales, A | 1 |
| Fareed, J | 1 |
| Hoppensteadt, D | 1 |
| Walenga, J | 1 |
| Iqbal, O | 1 |
| Ma, Q | 1 |
| Jeske, W | 1 |
| Sheikh, T | 1 |
| Hulot, JS | 2 |
| Vantelon, C | 1 |
| Urien, S | 2 |
| Bouzamondo, A | 1 |
| Mahé, I | 3 |
| Lechat, P | 2 |
| Quiles, J | 1 |
| Avanzas, P | 1 |
| Bueno, H | 1 |
| Bazinet, A | 1 |
| Almanric, K | 1 |
| Brunet, C | 1 |
| Turcotte, I | 1 |
| Martineau, J | 1 |
| Caron, S | 1 |
| Blais, N | 1 |
| Lalonde, L | 1 |
| Kane-Gill, SL | 1 |
| Feng, Y | 1 |
| Bobek, MB | 1 |
| Bies, RR | 1 |
| Pruchnicki, MC | 1 |
| Dasta, JF | 1 |
| Kravitz, MS | 1 |
| Mishaal, RA | 1 |
| Shoenfeld, Y | 1 |
| López-Sánchez, M | 1 |
| González-Fernandez, C | 1 |
| Valero-Díaz de Lamadrid, C | 1 |
| Domínguez-Artiga, MJ | 1 |
| Hernández-Hernández, MA | 1 |
| Lim, W | 1 |
| Dentali, F | 1 |
| Eikelboom, JW | 1 |
| Ellis, MH | 1 |
| Hadari, R | 1 |
| Tchuvrero, N | 1 |
| Shapira, S | 1 |
| Kovlenko, I | 1 |
| Kozmiakova, M | 1 |
| Zissin, R | 1 |
| Elis, A | 1 |
| Dharmarajan, TS | 1 |
| Sohagia, A | 1 |
| Gouin-Thibault, I | 1 |
| Drouet, L | 2 |
| Simoneau, G | 1 |
| Di Castillo, H | 1 |
| Siguret, V | 4 |
| Bergmann, JF | 2 |
| Pautas, E | 2 |
| Aghassarian, M | 1 |
| Bal Dit-Sollier, C | 1 |
| Lacut, K | 1 |
| Heilmann, JJ | 1 |
| Mottier, D | 3 |
| Cherfan, A | 1 |
| Arabi, Y | 1 |
| Al Askar, A | 1 |
| Al Shimemeri, A | 1 |
| Fox, KA | 1 |
| Antman, EM | 1 |
| Agewall, S | 1 |
| SomaRaju, B | 1 |
| Verheugt, FW | 1 |
| Lopez-Sendon, J | 1 |
| Hod, H | 1 |
| Murphy, SA | 1 |
| Braunwald, E | 1 |
| Joannidis, M | 1 |
| Kountchev, J | 1 |
| Rauchenzauner, M | 1 |
| Schusterschitz, N | 1 |
| Ulmer, H | 1 |
| Mayr, A | 1 |
| Bellmann, R | 1 |
| Despotovic, N | 1 |
| Erceg, P | 1 |
| Nikolic-Despotovic, M | 1 |
| Milosevic, DP | 1 |
| Davidovic, M | 1 |
| Lachish, T | 1 |
| Rudensky, B | 1 |
| Slotki, I | 1 |
| Zevin, S | 1 |
| Simons, R | 1 |
| Mallett, SV | 1 |
| Rodgers, GM | 2 |
| Gerlach, AT | 1 |
| Pickworth, KK | 1 |
| Seth, SK | 1 |
| Tanna, SB | 1 |
| Barnes, JF | 1 |
| Busby, LT | 1 |
| Weyman, A | 1 |
| Lison, L | 1 |
| Perry, DJ | 1 |
| Sanderink, GJ | 1 |
| Guimart, CG | 1 |
| Ozoux, ML | 1 |
| Jariwala, NU | 1 |
| Shukla, UA | 1 |
| Boutouyrie, BX | 1 |
| Andrassy, K | 1 |
| Kretzschmar, A | 1 |
| Díaz Gómez, E | 1 |
| Suárez Del Olmo, D | 1 |
| Corregidor Luna, L | 1 |
| Iglesias-Peinado, I | 1 |
| García Díaz, B | 1 |
| Dranitsaris, G | 1 |
| Shane, L | 1 |
| Burgers, L | 1 |
| Woodruff, S | 1 |
| Cook, D | 2 |
| Sinuff, T | 1 |
| Zytaruk, N | 2 |
| Rabbat, C | 2 |
| Lee, A | 1 |
| O'Donnell, M | 1 |
| Thabane, L | 1 |
| Linkins, L | 1 |
| Treleaven, D | 1 |
| Meade, M | 2 |
| Crowther, M | 2 |
| Marshall, JC | 1 |
| Douketis, J | 2 |
| Schmid, P | 1 |
| Brodmann, D | 1 |
| Fischer, AG | 1 |
| Wuillemin, WA | 1 |
| Knight, DJ | 1 |
| Selwyn, D | 1 |
| Girling, K | 1 |
| Rabbat, CG | 1 |
| McDonald, E | 1 |
| Clarke, F | 1 |
| Meade, MO | 1 |
| Lee, KA | 1 |
| Cook, RJ | 1 |
| Kani, C | 1 |
| Markantonis, SL | 1 |
| Nicolaou, C | 1 |
| Maggina, N | 1 |
| Tincani, E | 1 |
| Mannucci, C | 1 |
| Casolari, B | 1 |
| Turrini, F | 1 |
| Prisco, D | 1 |
| Cenci, AM | 1 |
| Bondi, M | 1 |
| Stöbe, J | 1 |
| Siegemund, A | 1 |
| Achenbach, H | 1 |
| Preiss, C | 1 |
| Preiss, R | 1 |
| Guyatt, G | 1 |
| Granton, J | 1 |
| Skrobik, Y | 1 |
| Albert, M | 1 |
| Fowler, R | 1 |
| Hebert, P | 1 |
| Pagliarello, G | 1 |
| Friedrich, J | 1 |
| Freitag, A | 1 |
| Karachi, T | 1 |
| Heels-Ansdell, D | 1 |
| Geerts, W | 1 |
| Fioretti, AM | 1 |
| Leopizzi, T | 1 |
| Puzzovivo, A | 1 |
| Giotta, F | 1 |
| Lorusso, V | 1 |
| Luzzi, G | 1 |
| Oliva, S | 1 |
| Yeung, J | 1 |
| Dix, CHK | 1 |
| Ritchie, AG | 1 |
| Kow, M | 1 |
| Chen, VMY | 1 |
| Leizorovicz, A | 2 |
| Clonier, F | 1 |
| Janas, M | 1 |
| Stinson, J | 1 |
| Townshend, G | 1 |
| Maddalena, M | 1 |
| Gouin, I | 1 |
| Bellot, O | 1 |
| Andreux, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function[NCT03158792] | Phase 4 | 32 participants (Actual) | Interventional | 2015-10-24 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency[NCT00927602] | Phase 4 | 206 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to study was stopped after enrolment of about 200 patients for slow recruitment) | ||
| Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099] | 140 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function[NCT00264693] | 96 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| Safety Profile of Innohep Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis[NCT00277394] | Phase 4 | 541 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00277394)
Timeframe: prior to day 90 +/- 5
| Intervention | Patients (Number) |
|---|---|
| Innohep® | 32 |
| Heparin | 32 |
(NCT00277394)
Timeframe: prior to day 90 +/- 5
| Intervention | Patients (Number) |
|---|---|
| Innohep® | 12 |
| Heparin | 10 |
(NCT00277394)
Timeframe: prior to day 90 +/- 5
| Intervention | Patients (Number) |
|---|---|
| Innohep® | 16 |
| Heparin | 9 |
9 reviews available for dalteparin and Renal Insufficiency
| Article | Year |
|---|---|
Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Nadroparin; Renal Insufficiency; Tinzapari | 2022 |
Preventing venous thromboembolism in critically ill patients.
Topics: Clinical Trials as Topic; Critical Illness; Dalteparin; Heparin; Humans; Intensive Care Units; Nadro | 2008 |
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.
Topics: Anticoagulants; Cardiovascular Diseases; Enoxaparin; Glomerular Filtration Rate; Hemorrhage; Humans; | 2012 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2012 |
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
Topics: Age Factors; Anticoagulants; Biological Availability; Clinical Trials as Topic; Enoxaparin; Female; | 2003 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Treating venous thromboembolism: enoxaparin.
Topics: Ambulatory Care; Anticoagulants; Contraindications; Cost-Benefit Analysis; Drug Costs; Enoxaparin; H | 2001 |
Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Topics: Biocompatible Materials; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Mol | 1993 |
Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review.
Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Renal Insufficiency; Thrombosis; Tinzaparin | 2022 |
22 trials available for dalteparin and Renal Insufficiency
| Article | Year |
|---|---|
Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study.
Topics: Aged; Anticoagulants; Blood Flow Velocity; Cross-Over Studies; Dalteparin; Double-Blind Method; Equi | 2000 |
Haemodialysis hypotension and nitric oxide production: comparison of heparin with parnaparin.
Topics: Adult; Blood Pressure; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Hypotension; Male; Mi | 2002 |
Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients.
Topics: Adult; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Female; Fibrinolytic Agents; Hepa | 1995 |
Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Male; Re | 2019 |
Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation Tests; Cardiac | 2010 |
Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Enoxaparin; Factor Xa; Female; Hum | 2003 |
Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Artery Disease; Creati | 2004 |
Dosage of enoxaparin among obese and renal impairment patients.
Topics: Aged; Blood Coagulation Tests; Body Weight; Cardiovascular Diseases; Drug Monitoring; Enoxaparin; Fa | 2005 |
Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Creatinine; Enoxap | 2007 |
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Blood Coagulation; Body Weight; Creatinine; Drug Administration Schedule; E | 2007 |
The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.
Topics: Aged; Aged, 80 and over; Creatinine; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; H | 2007 |
Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; APACHE; Cost-Benefit Analysis; Cross-Over Studies; E | 2007 |
Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; | 2007 |
Enoxaparin in unstable angina patients with renal failure.
Topics: Aged; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Humans; Male; Renal Insufficiency | 2001 |
Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Human | 2002 |
Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Heparin, | 2016 |
Prospective observational cohort study of bioaccumulation of dalteparin at a prophylactic dose in patients with peritoneal dialysis.
Topics: Aged; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; | 2010 |
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Topics: Anticoagulants; Creatinine; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intensive | 2005 |
Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2006 |
Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency.
Topics: Adolescent; Adult; Anticoagulants; Creatinine; Dalteparin; Factor Xa; Factor Xa Inhibitors; Female; | 2006 |
Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).
Topics: Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Female; Heparin; Heparin, Low | 2011 |
Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombin III; Atrial Fibrillation; Body Weight; Creatine; | 2002 |
42 other studies available for dalteparin and Renal Insufficiency
| Article | Year |
|---|---|
The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.
Topics: Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin; | 2023 |
Prevalence of correct anti-Xa levels in renally impaired patients who are on therapeutic nadroparin.
Topics: Aged; Anticoagulants; Factor Xa; Female; Glomerular Filtration Rate; Humans; Male; Nadroparin; Renal | 2018 |
No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency.
Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Injections, Subcutaneous; Male; Nadropar | 2015 |
Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins.
Topics: Anticoagulants; Calcinosis; Child; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Nadr | 2004 |
[Bleeding complication due to accumulation of low-molecular-weight heparin in a patient with renal insufficiency].
Topics: Acute Kidney Injury; Adolescent; Age Factors; Aged; Anticoagulants; Anuria; Child; Creatinine; Enoxa | 2007 |
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.
Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Human | 2020 |
Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Female; Heparin, Low-Molecular-Weight; | 2014 |
Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Intensive Care Units; Renal Insufficiency; | 2021 |
Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2018 |
Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment.
Topics: Adolescent; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Administration Schedule; Enoxa | 2019 |
Additional considerations to precede selection of enoxaparin therapy.
Topics: Enoxaparin; Female; Humans; Male; Renal Insufficiency; Thromboembolism | 2013 |
Additional considerations to precede selection of enoxaparin therapy--reply.
Topics: Enoxaparin; Female; Humans; Male; Renal Insufficiency; Thromboembolism | 2013 |
Drug-induced dilemma: angiokeratomas and decreased renal function.
Topics: Aged, 80 and over; Angiokeratoma; Anticoagulants; Drug Eruptions; Enoxaparin; Female; Humans; Renal | 2014 |
Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency - The PACER pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; | 2016 |
Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Dosage Calculations; | 2009 |
Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Hemorrhage; Hum | 2009 |
Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Heart Fail | 2011 |
Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Cohort Studies; Creatinine; | 2012 |
Utility, or not, of estimates of glomerular filtration rate in modifying drug dosage, with particular reference to enoxaparin.
Topics: Drug Dosage Calculations; Enoxaparin; Glomerular Filtration Rate; Humans; Kidney; Medical Errors; Re | 2012 |
Enoxaparin outcomes in patients with moderate renal impairment.
Topics: Aged; Anticoagulants; Creatinine; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up St | 2012 |
Moderate renal impairment and risk of bleeding with anticoagulation.
Topics: Enoxaparin; Female; Humans; Male; Renal Insufficiency; Thromboembolism | 2012 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function.
Topics: Aged; Angina, Unstable; Anticoagulants; Creatinine; Enoxaparin; Female; Hemorrhage; Humans; Kidney T | 2005 |
Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
Topics: Anticoagulants; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Female; Hospital Bed | 2005 |
Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Dose-Response Relationship, Drug; Enoxaparin; Fact | 2005 |
Renal failure and low molecular weight heparins. A dangerous liaison? The case of retroperitoneal hematoma.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Hematoma; Heparin, Low-Molecular-Weight; Humans | 2005 |
Enoxaparin, retroperitoneal haematoma in the elderly and impaired renal function.
Topics: Aged; Anticoagulants; Enoxaparin; Fatal Outcome; Female; Hematoma; Humans; Medication Errors; Radiog | 2005 |
Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Drug Evaluation; Enoxaparin; Female; Hemorrhag | 2006 |
Low-molecular-weight heparin and bleeding: how do we lower risk but maintain benefit?
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Renal Insufficiency; Risk Assessment | 2006 |
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
Topics: Aged; Angiography; Anticoagulants; Blood Component Transfusion; Clopidogrel; Drug Interactions; Embo | 2007 |
Bleeding during enoxaparin treatment more common with age over 75 years and severe renal insufficiency.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Endpoint Determination; Enoxapa | 2007 |
Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparin.
Topics: Aged; Anesthesia, Epidural; Anticoagulants; Blood Coagulation; Contraindications; Drug Administratio | 2007 |
Inappropriate use of enoxaparin in the treatment of deep-vein thrombosis.
Topics: Contraindications; Drug Approval; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Medication | 1999 |
Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Renal Dialysis; Ren | 2000 |
Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
Topics: Adult; Anticoagulants; Creatine; Drug Monitoring; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec | 2001 |
Topics: Aftercare; Aged; Ambulatory Care; Female; Heparin, Low-Molecular-Weight; Humans; Length of Stay; Mal | 2018 |
Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin.
Topics: Anticoagulants; Dalteparin; Humans; Renal Insufficiency; Retrospective Studies; Venous Thromboemboli | 2022 |
Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Critical Illne | 2009 |
Low-molecular-weight heparin for anticoagulation during continuous venovenous hemofiltration.
Topics: Anticoagulants; Critical Illness; Dalteparin; Drug Monitoring; Hemofiltration; Humans; Renal Insuffi | 2003 |
Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.
Topics: Aged; Anticoagulants; Critical Care; Critical Illness; Dalteparin; Female; Humans; Male; Observation | 2006 |
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Hemorrhage; Humans; Incidence; I | 2008 |
Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study.
Topics: Aged; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pilot Projects; Prospective Studies; Re | 2023 |